Coronavirus vaccine News Johnson and Johnson confirms Covid 19 vaccine trial paused on safety event

In the midst of the devastation of the Kovid-19 pandemic, the Corona virus vaccine continues to be developed. Meanwhile, the shocking news is that Johnson & Johnson has stopped the trial of its Corona vaccine. Johnson & Johnson has now stopped the trial of its Corona vaccine after a person taking part in a trial had some kind of illness.

Jake Sargent, a spokesman for the New Jersey company New Brunswick, corrected the STAT report, which provides health care news, and said Johnson & Johnson’s trial on the Corona virus vaccine had been halted.

Earlier this month, Johnson & Johnson joined the short list of vaccine makers in the US. Johnson & Johnson’s AD26-COV2-S vaccine is the fourth such vaccine in the US to be in the final stages of clinical trials. The previous report stated that the vaccine produced a strong immune response against the corona virus in preliminary studies. The researchers said that there were no serious side effects based on the test results so far.

When Johnson & Johnson began the final phase of the vaccine trial, the company said it would test 60,000 people in the US, South Africa, Brazil, Chile, Colombia, Mexico and Peru. The news of Johnson & Johnson’s vaccine trial being banned comes at a time when AstraZeneca’s vaccine was banned earlier.

Oxford University and AstraZeneca’s vaccine was at the forefront of the vaccine race, but Phase III trials had to be halted on September 6 when conditions worsened after some volunteers had taken the Covishield vaccine. However, there have been resumes in Britain and India. However, the US or other countries have not yet approved it again.


Disclaimer: The above information is for general informational purposes only. All information on the Site is provided in good faith, however we make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability or completeness of any information on the Site.